IDRI prides itself on being a “nonprofit biotech.” We combine the high-quality science of a research organization with the product development capability of a biotech company. Founded in 1993 and headquartered in Seattle, IDRI is focused on creating new products to combat infectious diseases of global importance.
Our portfolio of programs comprises diseases that kill millions of adults and children each year, while incapacitating millions more. These diseases have different causes, symptoms and global footprints. Despite these diverse challenges, we have a singular goal for each program: developing diagnostics, drugs and vaccines that save lives, improve health and relieve economic burdens.
Age-old diseases including tuberculosis, leishmaniasis and leprosy are the core diseases on which we focus, along with newly emerging diseases such as Zika, chikungunya and West Nile virus. Our expertise in adjuvant development and formulation extend our reach through more than 100 global partnerships to work on a range of diseases, including malaria, pandemic influenza, Chagas disease, hookworm, shistosomiasis and HIV/AIDS.
We apply innovative science to develop products to eliminate infectious diseases of global importance.
We envision a world in which infectious diseases are either prevented or rapidly diagnosed and treated using products that are available to all people.
Compassion: We are driven by compassion and the belief that all people should be free from infectious diseases. Our work holds the promise of saving millions of lives and improving quality of life.
Scientific Excellence: We are rooted in scientific excellence, respect for our colleagues and commitment to the creativity, integrity and discipline required to conduct our work.
Impact: We believe our research and development, through teamwork and innovation, will have significant impact to improve health locally and globally.